News-Details

New Framework Conditions for MedTech Innovations: Amendments to Sections 137e (clinical trials) and 137h (NUB) of SGB V

The Joint Federal Committee (GBA) has amended its rules of procedure to comply with the requirements of the Statutory Health Insurance Contribution Rate Stabilization Act. The new provisions expand the GBA benefit assessment under Section 137h of Book V of the Social Code (SGB V) for new examination and treatment methods (NUB) and modify the funding for clinical trials under Section 137e of SGB V.

On October 15, 2026, the Joint Federal Committee (GBA) adopted amendments to its Rules of Procedure regarding Sections 137e and 137h of Book V of the Social Code (SGB V). The resolution took effect on November 10th, 2026. With this, the GBA is implementing key provisions of the Statutory Health Insurance Contribution Rate Stabilization Act. 

One significant change concerns the testing of new examination and treatment methods under Section 137e of SGB V. If a clinical trial is requested by a medical device manufacturer or another company, the applicant must in the future, at its own expense, commission an independent scientific institution to provide scientific assistance and evaluation. 

In addition, the subject of the assessment procedure under Section 137h of SGB V is significantly expanded. The previous restriction to methods whose technical application relies primarily on high-risk-class medical devices has been removed. The scope now generally includes new inpatient examination and treatment methods based on a new theoretical-scientific concept and not solely on the administration of a drug. A prerequisite is that, for the first time, a NUB request for this method be submitted to InEK. 

MedTech companies would be well advised to take a close look at the new framework conditions. The current changes underscore how important it is to coordinate evidence strategy, reimbursement, and market access early on for the German healthcare market. 

Would you like to know how the amendments to Sections 137e and 137h of SGB V affect your MedTech innovation and your market access strategy? Please feel free to contact us.

Author: Healthcare Heads GmbH

Phone: +49 431 800 1470

E-Mail: info@healthcareheads.com